2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Kd019: new trials by email Literature Review of Kd019 trials Research Report on Kd019
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 tesevatinib - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | Terminated | Kadmon Corporation, LLC | 15 | 2015-12-25 | 2022-05-25 |
| Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Tesevatinib, Trastuzumab - HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain | Phase 1 / Phase 2 | Terminated | Kadmon Corporation, LLC | 17 | 2014-05-01 | 2022-04-27 |
Brain Neoplasms (1) · Polycystic Kidney, Autosomal Dominant (1)
United States (2)